The Efficacy Of Intermediate-Dose Cytarabine Consolidation Therapy For Acute Myeloid Leukemia

Objective:To investigate the efficacy of intermediate-dose cytarabine(ID-Ara-C) in the initial treatment of adult patients with acute myeloid leukemia(AML). Methods:From January of 2008 to December of 2013, screening for the adult patients were initial treatment,who accepted 1-2 DA or IA induction therapy achieved complete remission, and used the ID-Ara-C(Ara-C:1.0-1.5 g/m2 q12 h, d1, 3, 5) in the consolidation treatment 1-4courses, and the patient without allo-HSCT.There were 66 patients were selected.Research into the clinical data of the atients.The date was analyzed retrospectively. Analysis of the complete remission rate of patients in DA group and IA group.According to different consolidation therapy,patients were divided into 3 groups:1 ID-Ara-C,2 ID-Ara-C, 3-4ID-Ara-C 3 group,The complete remission(CR) rate, disease-free survival(DFS) and overall survival(OS) were analyzed. Results:66 patients were completely remission by1-2 therapy. There were 34、32 patients in DA group and IA group,accepted one therapy there were 58.8%(20/34)、68.8%(22/32)patients in DA group and IA group arrived completely remission。There were 41.2%(14/34)、31.2%(10/32)patients in DA group and IA group arrived completely remission accepted two therapy.The median follow-up time was 21 months,24 cases relapsed, and 43 cases died.Median DFS and OS were 19 and 21months. In 1 ID-Ara-C, 2 ID-Ara-C,3-4 ID-Ara-C group, the 3-year DFS were 0%,36.1% and 37.5% respectively, the 5-year DFS were 0%, 30.1% and 37.5% respectively,the 3-year OS were 24.0%,36.0% and 58.3% respectively, the 5-year OS were 0%,30.0%and 35.0% respectively.The multiple factor analysis indicated that courses of ID-Ara-C was independent risk factor for DFS and OS. Conclusion:≧2 ID-Ara-C may be used as one of the consolidation therapy of patients with AML. Courses of ID-Ara-C was independent risk factor for DFS and OS.